Benefits of vascular normalization are dose and time dependent - Letter

Cancer Research

Volumn 73, Issue 23, 2013, Pages 7144-7146

  Huang, Yuhui ^a   Stylianopoulos, Triantafyllos ^a   Duda, Dan G ^a   Fukumura, Dai ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY DC101;

ANTINEOPLASTIC ACTIVITY; ANTIVASCULAR ACTIVITY; BREAST CANCER; BREAST TUMOR; CANCER INHIBITION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; EXPERIMENTAL MOUSE; HUMAN; LETTER; LOW DRUG DOSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VASCULARIZATION;

EID: 84890282284     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1989     Document Type: Letter

References (5)

1. Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 2013;73:3347-55.
2. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013;31:2205-18.
3. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012;109:17561-6.
4. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012;7:383-8.
5. Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 2012;11:752-62.